Skip to main content
. 2013 Oct 16;15(5):R95. doi: 10.1186/bcr3556

Table 1.

Demographic and clinical characteristics for adolescents and young adults (15 to 39 years of age) with breast cancer by subtype*, California, 2005 through 2009

  Total
(n= 5,331)
HR+/HER2-*
(n= 2,191)
HR+/HER2+*
(n= 811)
HR-/HER2+*
(n= 469)
Triple negative
(n= 1014)
Unclassified
(n= 846)
Characteristics
n (Col%)
n (Col%)
n (Col%)
n (Col%)
n (Col%)
n (Col%)
Age at diagnosis
 
 
 
 
 
 
 15-29
560 (10.5%)
190 (8.7%)
88 (10.9%)
63 (13.4%)
108 (10.7%)
111 (13.1%)
 30-34
1,441 (27.0%)
525 (24.0%)
237 (29.2%)
141 (30.1%)
303 (29.9%)
235 (27.8%)
 35-39
3,330 (62.5%)
1476 (67.4%)
486 (59.9%)
265 (56.5%)
603 (59.5%)
500 (59.1%)
Race/ethnicity**
 
 
 
 
 
 
 NH White
2,247 (42.1%)
984 (44.9%)
321 (39.6%)
193 (41.2%)
404 (39.8%)
345 (40.8%)
 NH Black
388 (7.3%)
128 (5.8%)
60 (7.4%)
37 (7.9%)
106 (10.5%)
57 (6.7%)
 Hispanic
1,737 (32.6%)
645 (29.4%)
273 (33.7%)
163 (34.8%)
378 (37.3%)
278 (32.9%)
 NH Asian/Pacific Islander
914 (17.1%)
423 (19.3%)
153 (18.9%)
74 (15.8%)
120 (11.8%)
144 (17.0%)
 Other/unknown
45 (0.8%)
11 (0.5%)
<5
<5
6 (0.6%)
22 (2.6%)
Marital status at diagnosis
 
 
 
 
 
 
 Married
3,268 (61.3%)
1,338 (61.1%)
500 (61.7%)
320 (68.2%)
616 (60.7%)
494 (58.4%)
 Never married
1,527 (28.6%)
639 (29.2%)
242 (29.8%)
104 (22.2%)
287 (28.3%)
255 (30.1%)
 Previously married
380 (7.1%)
165 (7.5%)
56 (6.9%)
31 (6.6%)
83 (8.2%)
45 (5.3%)
 Unknown
156 (2.9%)
49 (2.2%)
13 (1.6%)
14 (3.0%)
28 (2.8%)
52 (6.1%)
Tumor grade†
 
 
 
 
 
 
 Low
2,090 (39.2%)
1,288 (58.8%)
323 (39.8%)
102 (21.7%)
91 (9.0%)
286 (33.8%)
 High
2,891 (54.2%)
821 (37.5%)
455 (56.1%)
340 (72.5%)
888 (87.6%)
387 (45.7%)
 Unknown/not stated
350 (6.6%)
82 (3.7%)
33 (4.1%)
27 (5.8%)
35 (3.5%)
173 (20.4%)
AJCC stage at diagnosis
 
 
 
 
 
 
 I
1,310 (24.6%)
660 (30.1%)
170 (21.0%)
86 (18.3%)
191 (18.8%)
203 (24.0%)
 II
2,328 (43.7%)
933 (42.6%)
354 (43.6%)
187 (39.9%)
515 (50.8%)
339 (40.1%)
 III
1,100 (20.6%)
425 (19.4%)
214 (26.4%)
130 (27.7%)
208 (20.5%)
123 (14.5%)
 IV
313 (5.9%)
115 (5.2%)
47 (5.8%)
47 (10.0%)
60 (5.9%)
44 (5.2%)
 Unknown/not stated
280 (5.3%)
58 (2.6%)
26 (3.2%)
19 (4.1%)
40 (3.9%)
137 (16.2%)
Tumor size (cm)
 
 
 
 
 
 
 <2.00
1,987 (37.3%)
969 (44.2%)
309 (38.1%)
147 (31.3%)
287 (28.3%)
275 (32.5%)
 2.01-5.00
2,261 (42.4%)
915 (41.8%)
350 (43.2%)
196 (41.8%)
500 (49.3%)
300 (35.5%)
 >5.00
734 (13.8%)
239 (10.9%)
115 (14.2%)
79 (16.8%)
176 (17.4%)
125 (14.8%)
 Microinvasion
57 (1.1%)
12 (0.5%)
9 (1.1%)
17 (3.6%)
13 (1.3%)
6 (0.7%)
 Diffuse
54 (1.0%)
15 (0.7%)
5 (0.6%)
7 (1.5%)
0
27 (3.2%)
 Unknown
238 (4.5%)
41 (1.9%)
23 (2.8%)
23 (4.9%)
38 (3.7%)
113 (13.4%)
Lymph nodes involvement
 
 
 
 
 
 
 No
2,563 (48.1%)
1,074 (49.0%)
333 (41.1%)
178 (38.0%)
532 (52.5%)
446 (52.7%)
 Positive
2,647 (49.7%)
1,098 (50.1%)
470 (58.0%)
282 (60.1%)
468 (46.2%)
329 (38.9%)
 Unknown
121 (2.3%)
19 (0.9%)
8 (1.0%)
9 (1.9%)
14 (1.4%)
71 (8.4%)
Metastasis status
 
 
 
 
 
 
 No
4,880 (91.5%)
2,050 (93.6%)
751 (92.6%)
411 (87.6%)
936 (92.3%)
732 (86.5%)
 Yes
316 (5.9%)
115 (5.2%)
47 (5.8%)
47 (10.0%)
61 (6.0%)
46 (5.4%)
 Unknown
135 (2.5%)
26 (1.2%)
13 (1.6%)
11 (2.3%)
17 (1.7%)
68 (8.0%)
Surgery
 
 
 
 
 
 
 No
362 (6.8%)
103 (4.7%)
47 (5.8%)
41 (8.7%)
64 (6.3%)
107 (12.6%)
 Yes
4,942 (92.7%)
2,077 (94.8%)
763 (94.1%)
428 (91.3%)
944 (93.1%)
730 (86.3%)
 Unknown
27 (0.5%)
11 (0.5%)
<5
0
6 (0.6%)
9 (1.1%)
Chemotherapy
 
 
 
 
 
 
 No
1,250 (23.4%)
588 (26.8%)
120 (14.8%)
67 (14.3%)
120 (11.8%)
355 (42.0%)
 Yes
3,986 (74.8%)
1,565 (71.4%)
678 (83.6%)
395 (84.2%)
886 (87.4%)
462 (54.6%)
 Unknown
95 (1.8%)
38 (1.7%)
13 (1.6%)
7 (1.5%)
8 (0.8%)
29 (3.4%)
Radiation therapy
 
 
 
 
 
 
 No
2,818 (52.9%)
1,110 (50.7%)
415 (51.2%)
244 (52.0%)
503 (49.6%)
546 (64.5%)
 Yes
2,509 (47.1%)
1,080 (49.3%)
396 (48.8%)
225 (48.0%)
511 (50.4%)
297 (35.1%)
 Unknown
<5
<5
0
0
0
<5
Neighborhood SES quintile
 
 
 
 
 
 
 1, lowest
875 (16.4%)
328 (15.0%)
135 (16.6%)
73 (15.6%)
183 (18.0%)
156 (18.4%)
 2
997 (18.7%)
392 (17.9%)
133 (16.4%)
97 (20.7%)
203 (20.0%)
172 (20.3%)
 3
1,051 (19.7%)
411 (18.8%)
163 (20.1%)
103 (22.0%)
197 (19.4%)
177 (20.9%)
 4
1,190 (22.3%)
524 (23.9%)
178 (21.9%)
100 (21.3%)
206 (20.3%)
182 (21.5%)
 5, highest
1,218 (22.8%)
536 (24.5%)
202 (24.9%)
96 (20.5%)
225 (22.2%)
159 (18.8%)
Insurance status‡
 
 
 
 
 
 
 Private/military insurance
3,637 (68.2%)
1564 (71.4%)
557 (68.7%)
310 (66.1%)
680 (67.1%)
526 (62.2%)
 Public insurance
1,109 (20.8%)
408 (18.6%)
175 (21.6%)
109 (23.2%)
234 (23.1%)
183 (21.6%)
 No insurance
93 (1.7%)
30 (1.4%)
16 (2.0%)
6 (1.3%)
13 (1.3%)
28 (3.3%)
 Unknown 492 (9.2%) 189 (8.6%) 63 (7.8%) 44 (9.4%) 87 (8.6%) 109 (12.9%)

* Human epidermal growth factor receptor 2 (HER2), hormone receptor (HR), triple-negative (estrogen-receptor negative, progesterone-receptor negative, HER2-negative).

** Non-Hispanic.

† Low grade was defined as tumor grade I and II; high grade was defined as tumor grade III.

‡ Public insurance included Medicaid and other government-assisted programs; private insurance included health maintenance organizations, preferred provider organizations, managed care not otherwise specified, and military care.